

# Nuts and bolts of exosomes in aesthetic medicine

*Hernán Pinto*

i2e3 Biomedical Research Institute, Santa Coloma de Gramenet, Spain

**Abstract.** Over the past decade, the body of knowledge about the behavior and properties of exosomes has grown exponentially, resulting in an overwhelming number of published scientific articles. Exosomes are constitutively synthesized and released by many human cells, plants, animal cells, and even bacteria. Exosomes can be derived from the patient's tissues (autologous exosomes), from other human tissues (allogenic exosomes), and plants, animals, or bacteria (xenogenic exosomes). Exosomes offer innovative treatment options in medical aesthetics, such as repairing, regenerating, and rejuvenating skin tissue, preventing and reducing scarring, regulating pigmentation, promoting hair growth, and increasing the survival of fat grafts in aesthetic treatments. However, the significant cost of production is a clear indication of the industry's first steps in its development. Furthermore, performing these therapies in a private medical office is expensive, and the technical requirements need an in-depth analysis. The key points identified as corrupting, misleading, or confusing concepts (source, cargo, process of origin, and quantity) should be clarified. For all the above, more clinical trials need to be conducted for regulatory approval because, to our knowledge, no exosome-based products or therapies have been approved by any regulatory agency. Nonetheless, exosome treatments undoubtedly represent a breakthrough for aesthetic regenerative medicine.

**Key words:** exosomes, transport vesicles, cosmeceuticals, regenerative medicine, wound healing, skin rejuvenation

## Introduction

Exosomes are cell-derived nanovesicles that transport proteins, all sorts of nucleic acids and lipids, and play a significant role in almost every physiological process that takes place in the human body. Cells and platelets release exosomes constitutively, and their function, based on what is known so far, is to communicate with neighboring or distant cells<sup>1</sup> facilitating a coordinated tissular response to virtually any stimulus. Exosomes possess unique physicochemical properties, such as a low degree of antigenicity and a great capability to cross tissue barriers or escape from mononuclear phagocytic cell systems<sup>2</sup>.

In the last decade, evidence on exosome behavior and characteristics grew exponentially and led to an overwhelming number of published scientific

articles. Similarly, to what happened with cell therapies, exosomes were initially regarded as just another promising tool within the regenerative medicine armamentarium. However, because of their easier manipulation requirements and a better safety profile when compared to cells, they are now skyrocketing the medical community's interest. Exosome therapies have added advantages that cannot be overlooked, such as: i) high long-term stability, ii) high targeting capacity that will surely be able to improve drug efficacy and delivery, and iii) cargo capabilities, among others. Today, they can be procured from bone marrow, placenta, adipose tissue, blood, umbilical cord, and they have been found in every tissue and body fluid. Exosomes offer innovative treatment options for repairing, regenerating, and rejuvenating skin tissues, preventing and reducing scarring, regulating pigmentation, promoting

hair growth, and increasing fat graft survival in aesthetic treatments<sup>1,2</sup>.

Some clinical trials (CTs) have probed the efficacy of exosomes in all sorts of strategies and diseases: COVID-19<sup>3</sup>, colorectal cancer<sup>4</sup>, antitumor immunity<sup>5</sup>, chronic kidney diseases<sup>6</sup>, or wound healing<sup>7</sup>. There are few CTs on aesthetic medicine, and many of them are still recruiting (i.e. NCT05658094, NCT02565264, NCT05969717), unknown status (i.e. NCT02565264, NCT02737267), or have been completed without published results (i.e. NCT05523011, NCT05475418, NCT03459703).

Regenerative medical procedures are usually manual-based and require highly skilled operators<sup>8</sup>, determining very limited yield and high production costs. Since biological materials must be procured from and readministered to a human being, medical facilities and specialized personnel requirements are drawn major attention. The significant initial expenses of implementing any of these therapies in a private medical consultation had to be evaluated thoroughly. Understandably, the overall costs of shifting from conventional to regenerative therapies resulted in a delayed implementation of aesthetic regenerative treatments. Finally, the lack of a thorough understanding of the action mechanism and the absence of legal regulations constituted two more barriers that restricted the implementation of aesthetic regenerative therapies and stood between the patient's interest and physician's treatment eligibility.

Additional considerations must be taken into account when facing the utilization of exosomes in aesthetic regenerative medicine, since processing procedures and techniques (grafting, isolation, purification, optimization, administration) are not fully agreed upon. The standardization of future procedures and clinical guidelines should overcome this otherwise huge obstacle for proper clinical implementation. The development of standardized quality control procedures and a more comprehensive understanding of the molecular communication between exosomes and their target cells would be beneficial<sup>9</sup>. To date, numerous researchers and health centers have already developed their own manufacturing processes. However, the effective transference of these achievements to the clinical field remains elusive. Further clinical trials are

required for regulatory clearance since no exosome-based products or therapies are, to our knowledge, currently approved by any regulatory agency<sup>10</sup>. The need for precise guidelines, recommendations, and regulations for their use in the aesthetic field is urgent. The aim of this manuscript is to deal with the so far identified and pinpointed issues that currently pervert the medical communication and impair the commercialization and proper usage of exosome-based products in the European aesthetic medicine market. We do not intend to compare commercial products, but aim to assess the problems that determine whether they are truly or legally accepted as such.

### **Exosomes in the aesthetic medical field**

Undoubtedly, exosome treatments represent a breakthrough for aesthetic regenerative medicine. However, the line between reality and science fiction has been blurred, and some things should be clarified without further delay. Four major key points have been identified as corrupting, misleading, or confusion-spreading concepts: a) source, b) cargo, c) process of origin, and d) quantity.

#### *Source*

As previously mentioned, exosomes are constitutively synthesized and released by all sorts of cells, and even by sub-cellular structures, such as platelets<sup>11</sup>. This occurs in every living organism and on a regular basis. Exosomes can be grafted from the patient's own tissues or from other human tissues. The first are autologous exosomes, the latter, allogenic. Exosomes can also be obtained from plants or animal cells, and even from bacteria. All these can be considered xenogenic exosomes. Technically, lexical inconsistencies and some minor terminological discrepancies can be found in the literature, but, for the sake of clarity, we will categorize exosomes as they were described.

Legislation voids are currently being exploited by commercial companies that are making a profit from the eagerness in the market towards exosome products<sup>12</sup>. However, having less regulations than desired does not mean a total lack of them<sup>13-15</sup>. In Spain and

great part of Europe, to the current knowledge of the author, there is not a single certified injectable exosome product. Allogenic exosome high-end products are dealing with regulatory entities, trying to certify their isolation and concentration procedures. Their alleged little antigenicity will require a paradigm shift and consume time and efforts to produce a great amount of high-quality evidence. Allogenic injectable exosomes will become a reality and the gold standard in the future. In the present moment, however, they are left only for top research players and their clinical implementation in standard medical consultations is not legal and stands closer to science fiction than reality.

On the other hand, autologous exosomes are currently the only possible injectable option, which is quite a meaningful observation. Some commercial efforts have developed new techniques to improve orthobiologic materials and were able to achieve secretomes with higher regenerative power that contain huge amounts of autologous exosomes. They are subjected to the same regulations as any other autologous treatment, such as PRP. This is the case of Photothermal Biomodulation (Meta Cell Technology, Spain) or artisanal filtration-ultracentrifugation.

Finally, there are cosmetic exosome-based products. The European legislation currently forbids human-origin molecules in cosmetic products, thus leaving the door open solely for non-human exosome cosmetic-based products. Of course, INCI and public health report requirements must be met, but it is fair to say that some allogenic non-human exosome-based cosmetic products are currently being commercialized (e.g.: Xoglo™, Purasomes™, Exo-Skin™)<sup>16</sup>.

### *Cargo*

Another issue that should be a concern for the medical community is the rationale behind exosome-based treatment indications. That is to say: does the indication make any sense? Exosomes are nanovesicles with a membrane and a cargo. The bi-lipidic layer membrane expresses tetraspanins and many other surface proteins. The cargo varies among each exosome, but in general, they can be loaded with proteins, nucleic acids, and all sorts of molecules, such as: RAB, ANNEXINS, mRNAs, CD63/81/9, HSP 60/70/90,

miRNAs, lncRNAs, ESCRT, SNARE, DNA, or OPNs, among many others.

Exosomes may differ in functionality, being involved in diagnostic and/or therapeutic procedures. The detection of any surface protein can lead to the identification of certain exosomes, which in turn could account for a certain physio-pathological status. This is closely related to the exosome's wonderful diagnostic possibilities. On the other hand, the therapeutic capabilities of exosomes will be almost solely related to their content. Exosomes can exert an epigenetic action, determining, for example, major down regulations of specific protein synthesis on target cells, among other actions<sup>17</sup>.

Cosmetic exosome-based products can have a physical as well a chemical action, but always limited to certain superficial layers of the skin. On the contrary, the effects of any injected product should be more ambitious, targeting broader regions, deeper tissues, or even a systemic action. Regardless of their cosmetic benefits, an unavoidable question stands out. Besides the regulation that explicitly forbids the injection of cosmetic products, and leaving aside the temerity of attempting a parenteral administration of something that was not meant to be injected: what would the epigenetic benefits that patients would obtain from an animal, vegetal or bacterial exosome be? Avoiding the answer to this question shows a lack of understanding the way exosomes act and their aim or physiological reason-to-be.

### *Process of origin*

Naïve exosomes are naturally synthesized by our own bodies<sup>17</sup>, as opposed to bioengineered exosomes that are the result of laboratory manipulations. The stimulation and favoring of naïve exosomes' release and collection is gaining adepts worldwide for its resembling innocuity, while being able to deliver higher regenerative power. Therapies like photothermal biostimulation help release exosomes from PRP platelets and play a major role in freeing the tethered ones.

For now, naïve exosomes allow physicians to comply with regulations, since they do not require standardized isolation and processing methods. These are extemporaneous products that remain under the same

regulation of the ortho-biologics that gave origin to exosomes (eg.: PRP, SVF). On the other hand, bioengineered exosomes must be very clear on the yield and purity, which will vary depending on the method used. The isolation and purification of exosomes at a large scale is not a great problem for naïve exosomes but can be one of the most important obstacles for bioengineered exosomes<sup>18,19</sup>. The same applies to storage.

### Quantity

In aesthetic medicine, every time something attracts rocket-high-level interest, we witness a commercial race. It has happened before many times, and it is happening right now with exosomes. The most relevant echoes of this race are found in the quantity of exosomes per vials being advertised: 1 billion, 10 billion, 50 billion... infinity. As goes, the questions that physicians avoid asking are always the ones underlying the importance of the number of exosomes per vial.

First, what do you want to achieve with this treatment? Unless the answer to this question is related to the skin benefits of a cosmeceutical product, the number of exosomes in the vial is irrelevant and does not make any sense because they cannot be injected. Second, what are the active ingredients of the product? Unless the answer to this question is related to animal, vegetal or bacterial components, the number of exosomes in the vial is irrelevant and does not make any sense because cosmeceuticals with human derivatives cannot be commercialized. Lastly, where do you get this product from? Unless the answer to this question is related to certified medical devices or legally commercialized cosmetics, the number of exosomes in the vial is irrelevant and does not make any sense because manual preparations cannot currently be commercialized.

### Conclusions

Exosomes have an incredible potential for aesthetic medicine and general health issues. The future seems bright when we consider the endless possibilities of a bioengineered low antigenic target-electable therapy. But this is the future. Currently, aesthetic

physicians can benefit from this therapy in very limited ways: i) allogenic exosomes from approved non-human cosmeceuticals, and ii) naïve autologous exosomes derived from processes that improve PRP-like products, such as photothermal biomodulation.

**Conflict of Interest:** The author has no conflicts of interest or financial ties to disclose.

**Funding:** This work has not received any funding.

### References

1. Xiong M, Zhang Q, Hu W, et al. The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. *Pharmacol Res.* 2021; 166:105490.
2. Zhang B, Gong J, He L, et al. Exosomes based advancements for application in medical aesthetics. *Front Bioeng Biotechnol.* 2022; 10:1083640.
3. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. *Stem Cells Dev.* 2020; 29(12):747-754.
4. Dai S, Wei D, Wu Z, et al. Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer. *Mol Ther.* 2008; 16(4):782-790.
5. Besse B, Charrier M, Lapiere V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. *Oncoimmunology.* 2016; 5(4):e1071008.
6. Nassar W, El-Ansary M, Sabry D, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. *Biomater Res.* 2016; 20:21.
7. Tan ST, Aisyah PB, Firmansyah Y, Nathasia N, Budi E, Hendrawan S. Effectiveness of Secretome from Human Umbilical Cord Mesenchymal Stem Cells in Gel (10% SM-hUCMSC Gel) for Chronic Wounds (Diabetic and Trophic Ulcer) - Phase 2 Clinical Trial. *J Multidiscip Healthc.* 2023; 16:1763-1777.
8. Moutsatsou P, Ochs J, Schmitt RH, Hewitt CJ, Hanga MP. Automation in cell and gene therapy manufacturing: from past to future. *Biotechnol Lett.* 2019; 41(11):1245-1253.
9. Brembilla NC, Vuagnat H, Boehncke WH, Krause KH, Preynat-Seauve O. Adipose-Derived Stromal Cells for Chronic Wounds: Scientific Evidence and Roadmap Toward Clinical Practice. *Stem Cells Transl Med.* 2023; 12(1):17-25.
10. Ku YC, Sulaiman HO, Anderson SR, Abtahi AR. The Potential Role of Exosomes in Aesthetic Plastic Surgery:

- A Review of Current Literature. *Plast Reconstr Surg Glob Open*. 2023; 11(6):e5051.
11. Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. *Cell Commun Signal*. 2021; 19(1):47.
  12. Asadpour A, Yahaya BH, Bicknell K, Cottrell GS, Widera D. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes. *Stem Cell Res Ther*. 2023; 14(1):111.
  13. Turner L. The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions. *Cell Stem Cell*. 2021; 28(11):1891-1895.
  14. Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. *J Extracell Vesicles*. 2015; 4:30087.
  15. ISEV2023 Abstract Book. *J Extracell Vesicles*. 2023; 12(S1).
  16. Song Y, Kim Y, Ha S, et al. The emerging role of exosomes as novel therapeutics: Biology, technologies, clinical applications, and the next. *Am J Reprod Immunol*. 2021; 85(2):e13329.
  17. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. *Science*. 2020; 367(6478):eaau6977.
  18. Yi YW, Lee JH, Kim SY, et al. Advances in Analysis of Biodistribution of Exosomes by Molecular Imaging. *Int J Mol Sci*. 2020; 21(2):665.
  19. Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications. *Int J Nanomedicine*. 2020; 15:6917-6934.
- 
- Correspondence:**  
Received: 17 November 2023  
Accepted: 14 February 2024  
Hernán Pinto, MD  
Instituto de Investigaciones Biomédicas i2e3. Santa Coloma de Gramenet, Spain  
E-mail: hpinto@i2e3.com  
Phone: +34 931703868